Therapeutic monoclonal antibodies in clinical neurology;Therapeutische monoklonale antikörper in der neurologie

Nervenarzt

Volumn 81, Issue 6, 2010, Pages 753-766

  Buttmann, M ^a   Wiendl, H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alzheimer; Multiple sclerosis; Natalizumab; Progressive multifocal leucoencephalopathy; Rituximab

Indexed keywords

ALEMTUZUMAB; BAPINEUZUMAB; BEVACIZUMAB; DACLIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NEURADIAB; NIMOTUZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; SOLANEZUMAB; UNCLASSIFIED DRUG; CANCER ANTIBODY; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG SAFETY; GLIOBLASTOMA; HUMAN; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; MUSCLE DISEASE; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; POLYNEUROPATHY; REVIEW; RISK ASSESSMENT; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTIONS; RECOMBINANT PROTEINS;

EID: 77955665041     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-2947-2     Document Type: Review

References (43)

1. Gold R, Hartung HP, Hohlfeld R et al (2009) Therapie der Multiplen Sklerose mit monoklonalen Antikörpern - Ergebnisse und Empfehlungen einer Arbeitstagung des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft. Akt Neurol 36:334-344
2. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
3. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643-646
4. Jones PT, Dear PH, Foote J et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525
5. Lofgren JA, Dhandapani S, Pennucci JJ et al (2007) Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 178:7467-7472
6. Dörner T, Isenberg D, Jayne D et al (2009) Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9:82-89
7. Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834-4840
8. Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98-108
9. Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
10. Calabresi PA, Giovannoni G, Confavreux C et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391-1403
11. Knowles WA, Pipkin P, Andrews N et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115-123
12. Rossi A, Delbue S, Mazziotti R et al (2007) Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 79:408-412
13. Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816-824
14. Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med (in press)
15. Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431-441
16. Brickelmaier M, Lugovskoy A, Kartikeyan R et al (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53:1840-1849
17. Elphick GF, Querbes W, Jordan JA et al (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380-1383
18. Stüve O, Wiendl H (2009) Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology 73:1346-1347
19. Bergamaschi R, Montomoli C (2009) Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler 15:1532-1533
20. Ismail A, Kemp J, Sharrack B (2009) Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol 256:1771-1772
21. Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647-648
22. Schweikert A, Kremer M, Ringel F et al (2009) Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 66:403-406
23. Coles AJ, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801
24. Bielekova B, Catalfamo M, Reichert-Scrivner S et al (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103:5941-5946
25. Montalban X, Wynn D, Kaufman M et al (2007) Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) Oral presentation 50
26. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688 (Pubitemid 351240747)
27. Hawker K, O'Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460-471
28. Buttmann M, Rieckmann P (2008) Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 8:433-455
29. Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485-1489
30. Cayrol R, Saikali P, Vincent T (2009) Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann N Y Acad Sci 1173:478-486
31. Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630-643
32. Kinoshita M, Nakatsuji Y, Kimura T et al (2009) Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386:623-627
33. Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
34. Jacob A, Weinshenker BG Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443-1448
35. Argyriou AA (2009) Molecularly targeted therapies for dysimmune neuropathies. Mol Med 15:283-287
36. Zebardast N, Patwa HS, Novella SP, Goldstein JM (2009) Rituximab in the management of refractory myasthenia gravis. Muscle Nerve
37. Wiendl H (2008) Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 5:548-557
38. Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536-1544
39. Greenberg SA (2010) Comment on alemtuzumab and inclusion body myositis. Brain (in press)
40. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
41. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
42. Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581-592
43. Jicha GA (2009) Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin Biol Ther 9:481-491